Tyrosine kinase inhibitors (TKIs) against the human epidermal growth factor receptor
(EGFR) are now standard treatment in the clinic for patients with advanced EGFR mutant …

TPS8102 Background: EGFR-TKI is the recommended treatment for patients with advanced
NSCLC who have an EGFR-TKI-sensitizing mutation (EGFRm). However, most patients …

Gefitinib, erlotinib and afatinib are approved for first‐line treatment of advanced non‐small
cell lung cancer (NSCLC) bearing an activating epidermal growth factor receptor (EGFR) …

Non-small-cell lung cancer (NSCLC) patients whose tumors have an EGFR-activating
mutation develop acquired resistance after a median of 9–11 months from the beginning of …

Background: Erlotinib is a selective epidermal growth factor receptor tyrosine kinase
inhibitor (EGFR-TKI). We conducted two phase II studies (JO16565 and JO18396) of …

LBA7502 Background: Orally administered ARQ197 is a selective, non-ATP competitive
inhibitor of c-MET (MET), a receptor TK implicated in cancer cell migration, invasion, and …

The epidermal growth factor receptor (EGFR) is among the most important targets in the
treatment of advanced non-small cell lung cancer (NSCLC). Erlotinib and gefitinib, two small …

The FLAURA trial established osimertinib, a third-generation epidermal growth factor
receptor (EGFR) tyrosine kinase inhibitor (TKI), as a viable first-line therapy in non-small cell …

EGFR mutations are well established as important oncogenic drivers that occur in 10–44%
of primary lung adenocarcinomas occurring more frequently in women, Asians and non …

First-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs),
gefitinib and erlotinib, produce reliable responses and survival benefits in selected patients …